Iradimed (IRMD) EBIAT (2016 - 2025)
Historic EBIAT for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $5.6 million.
- Iradimed's EBIAT rose 1043.99% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 1373.22%. This contributed to the annual value of $19.2 million for FY2024, which is 1187.27% up from last year.
- Per Iradimed's latest filing, its EBIAT stood at $5.6 million for Q3 2025, which was up 1043.99% from $5.8 million recorded in Q2 2025.
- Iradimed's 5-year EBIAT high stood at $5.8 million for Q2 2025, and its period low was $1.4 million during Q1 2021.
- For the 5-year period, Iradimed's EBIAT averaged around $3.9 million, with its median value being $4.1 million (2024).
- Within the past 5 years, the most significant YoY rise in Iradimed's EBIAT was 51069.68% (2021), while the steepest drop was 2161.2% (2021).
- Over the past 5 years, Iradimed's EBIAT (Quarter) stood at $3.9 million in 2021, then fell by 5.63% to $3.7 million in 2022, then grew by 23.58% to $4.5 million in 2023, then increased by 13.37% to $5.1 million in 2024, then grew by 8.35% to $5.6 million in 2025.
- Its EBIAT stands at $5.6 million for Q3 2025, versus $5.8 million for Q2 2025 and $4.7 million for Q1 2025.